Relmada Therapeutics
$7.26
38
+$0.09+1.26% Wednesday 20:00
Statistics
Day High
7.39
Day Low
7.15
52W High
7.86
52W Low
0.54
Volume
718,502
Avg. Volume
-
Mkt Cap
240.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
11AugExpected
Expected EPS
-0.19344
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-159.96MNet Income
Analyst Ratings
12.4Average Price Target
The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow RLMD. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap6.13B
Johnson & Johnson
JNJ
Mkt Cap564.11B
Lilly(Eli) &
LLY
Mkt Cap949.7B
Pfizer
PFE
Mkt Cap147.62B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap39.67B
Novartis
NVS
Mkt Cap290.05B
Merck
MRK
Mkt Cap302.33B
Abbvie
ABBV
Mkt Cap381.1B
Bristol-Myers Squibb
BMY
Mkt Cap121.42B
About
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Show more...
CEO
Dr. Sergio Traversa M.B.A., Pharm.D.
Employees
17
Country
United States
ISIN
US75955J4022
Listings
0 Comments
Share your thoughts
FAQ
What is Relmada Therapeutics stock price today?▼
The current price of RLMD is $7.26 USD — it has increased by +1.26% in the past 24 hours. Watch Relmada Therapeutics stock price performance more closely on the chart.
What is Relmada Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Relmada Therapeutics stocks are traded under the ticker RLMD.
Is Relmada Therapeutics stock price growing?▼
RLMD stock has risen by +0.69% compared to the previous week, the month change is a +0.28% rise, over the last year Relmada Therapeutics has showed a +901.52% increase.
What is Relmada Therapeutics market cap?▼
Today Relmada Therapeutics has the market capitalization of 240.97M
When is the next Relmada Therapeutics earnings date?▼
Relmada Therapeutics is going to release the next earnings report on August 11, 2026.
What were Relmada Therapeutics earnings last quarter?▼
RLMD earnings for the last quarter are -0.22 USD per share, whereas the estimation was -0.2 USD resulting in a -9.81% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Relmada Therapeutics revenue for the last year?▼
Relmada Therapeutics revenue for the last year amounts to 0 USD.
What is Relmada Therapeutics net income for the last year?▼
RLMD net income for the last year is -159.96M USD.
How many employees does Relmada Therapeutics have?▼
As of May 28, 2026, the company has 17 employees.
In which sector is Relmada Therapeutics located?▼
Relmada Therapeutics operates in the Health & Wellness sector.
When did Relmada Therapeutics complete a stock split?▼
The last stock split for Relmada Therapeutics was on September 30, 2019 with a ratio of 1:4.
Where is Relmada Therapeutics headquartered?▼
Relmada Therapeutics is headquartered in Coral Gables, United States.